MYC proteins are major drivers of cancer yet are considered undruggable because their DNA binding domains are composed of two extended alpha helices with no apparent surfaces for small-molecule binding. Proteolytic degradation of MYCN protein is regulated in part by a kinase-independent function of Aurora A. We describe a class of inhibitors that disrupts the native conformation of Aurora A and drives the degradation of MYCN protein across MYCN-driven cancers. Comparison of cocrystal structures with structure-activity relationships across multiple inhibitors and chemotypes, coupled with mechanistic studies and biochemical assays, delineates an Aurora A conformation-specific effect on proteolytic degradation of MYCN, rather than simple nanomolar-level inhibition of Aurora A kinase activity.
INTRODUCTION
MYC proteins are considered undruggable because their DNAbinding domains are composed of two extended alpha helices with no apparent surfaces for small-molecule binding. MYC also regulates as much as a third of the genome, with overexpression proposed to amplify cell-type-specific gene expression rather than modulate a MYC-specific group of genes (Lin et al., 2012; Nie et al., 2012) . The transcription of both MYC and MYCN targets may be blocked through bromodomain inhibitors (Delmore et al., 2011; Filippakopoulos et al., 2010; Mertz et al., 2011) . Other methods, such as synthetic lethal screens for potential targets, have revealed druggable targets that may act downstream of MYC (Gustafson and Weiss, 2010; Toyoshima et al., 2012) . Using an inducible dominant negative MYC protein, others have shown that systemic MYC inhibition is a viable cancer therapeutic strategy (Soucek et al., 2013) . However, using current medicinal chemistry, direct and efficient pharmacological targeting of MYC transcription factors has proven challenging, if not impossible (Prochownik and Vogt, 2010) .
MYC genes contribute to a wide range of human tumors through overexpression, amplification, translocation, or stabilization of point mutations. The normal concentration of MYC in cells is tightly regulated at the level of protein stability through canonical upstream kinase signaling pathways, including phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), cyclin-dependent kinase 2 (CDK2), and mitogen-activated protein kinase (MAPK). These kinases direct sequential Significance MYC genes contribute to a range of cancers, including neuroblastoma and medulloblastoma, where amplification confers a poor prognosis. MYC also regulates as much as a third of the genome, with overexpression proposed to amplify cell-typespecific gene expression. Despite their prominence in cancer, MYC proteins are considered undruggable. We synthesize and characterize a class of conformation-disrupting inhibitors of Aurora A that destabilize interactions between Aurora A and MYCN. These small molecules represent candidate agents to target MYC and MYCN-driven cancers, as well as prototypes for inhibitors that induce an allosteric change to block nonenzymatic functions of kinases.
phosphorylation and dephosphorylation of conserved residues in MYC proteins, which target them for ubiquitination and degradation by the proteasome (reviewed in Gustafson and Weiss, 2010) .
The MYC family member MYCN, named based on its association with MYCN amplification in the childhood tumor neuroblastoma, is stabilized by Aurora A in a kinase-independent fashion involving protein-protein interaction (Otto et al., 2009) . Independent of its effects on MYCN, Aurora A is an attractive cancer target because it regulates entry into mitosis, maturation of centrosomes, cytokinesis, and formation of the bipolar spindle, in part through the phosphorylation of key regulators of proliferation and survival such as p53, BRCA1, and histone H3 (Crosio et al., 2002; Liu et al., 2004; Ouchi et al., 2004; Scrittori et al., 2001; Zhao et al., 2008) . Increased Aurora A expression is a negative prognostic factor in neuroblastoma (Shang et al., 2009) , and preclinical testing with MLN8237, a specific Aurora A inhibitor, showed significant promise in cell-line xenograft experiments (Maris et al., 2010) . Furthermore, the cocrystal structure of MLN8054 (the predecessor of MLN8237) with Aurora A shows a partial shift away from the active state of the kinase, and treatment of MYCN-expressing neuroblastoma with MLN8237 or MLN8054 modestly decreases MYCN (Brockmann et al., 2013; Dodson et al., 2010) . This partial effect on MYCN of these compounds may therefore result from the prolonged inhibition of Aurora A kinase activity or a partial shift in the tertiary structure of Aurora A, which subtly weakens the MYCN-Aurora-A complex. Consistent with this modest effect on MYCN, early-phase clinical testing of MLN8237 in patients with MYCN-amplified neuroblastoma has shown little efficacy, underscoring the need for inhibitors of Aurora A that more potently block MYCN (Mossé et al., 2012) .
RESULTS

Initial Screen for Conformation-Disrupting Aurora A Inhibitors
We hypothesized that the kinase-independent stabilization of MYCN requires a distinct conformation of Aurora A and that we could rationally design specific and potent conformation-disrupting (CD) inhibitors that perturb this protein-protein interaction, effecting the degradation of MYCN. To identify such CD inhibitors we synthesized a set of compounds with either diaminopyrimidine (VX-680-like) or pyrazolopyrimidine (PP-1-like) scaffolds ( Figure 1A ) predicted to induce a large structural shift in Aurora A. Derivatives of each of these scaffolds were known to bind to Aurora A. Structural data were available on both scaffolds bound to related kinases, and the routes to their synthesis were tractable. To these ATP-competitive cores, we fused biphenyl urea and amide moieties predicted to stabilize distinct conformations of Aurora A (Dietrich et al., 2010; Filomia et al., 2010) .
To test whether this panel of 32 putative CD inhibitors would destabilize MYCN, we initially treated Kelly MYCN-amplified neuroblastoma cells with these compounds and measured MYCN protein using western blot. We also assessed for the phosphorylation of histone H3 (p-H3), a known substrate for Aurora A and Aurora B and a marker for mitosis. Treatment with several members of the screening panel decreased levels of both MYCN and p-H3 ( Figure 1B ; Figure S1A available online). In contrast, and as predicted, known inhibitors of Aurora A, VX-680 and MLN8237, blocked histone H3 phosphorylation at 1 mM yet demonstrated very modest effects on the MYCN protein level. Candidate CD inhibitors were subsequently screened against a second MYCN-amplified neuroblastoma cell line, SKN-BE(2) ( Figure 1C ), substantiating CD532 as our most active lead compound.
CD532 Potently Inhibits Aurora A, Causes Loss of MYCN, and Is Cytotoxic in MYCN-Amplified Neuroblastoma Cells
To determine the potency of CD532, we first measured its activity using purified Aurora A protein and revealed it as a potent Aurora A kinase inhibitor with an half maximal inhibitory concentration (IC 50 ) of 45 nM (Figures S1B and S1C). CD532 inhibited Aurora A kinase activity in cells as measured by both phosphorylated Aurora A (T288) and p-H3 at short time points to rule out off-target effects ( Figure S1D ). The treatment of multiple cell lines with CD532, MLN8237, and VX-680 showed dosedependent loss of MYCN protein with CD532 and little or no response to high concentrations of MLN8237 ( Figure 1D ; Figures S1E and S1F).
MLN8237 is a relatively selective inhibitor of Aurora A with a IC 50 of 1.2 nM and 396.5 nM for Aurora A and Aurora B, respectively, whereas VX-680 is potent against both Aurora A and Aurora B, with a IC 50 of 0.6 nM and 18 nM, respectively (Harrington et al., 2004; Lin et al., 2012; Manfredi et al., 2011; Nie et al., 2012; Otto et al., 2009) . Notably, the in vitro (cell-line) activity of CD532 against MYCN paralleled its cell-free in vitro IC 50 for Aurora A by approximately 10-fold (Figures 1D; Figures S1E and S1F). By contrast, MLN8237 and VX-680 treatment effected little loss of MYCN protein, even at doses 100 to 1,000 times greater than their IC 50 for Aurora A. MLN8237 and VX-680 upregulated or had little effect on Aurora A protein. CD532, in contrast, downregulated Aurora A protein across cell lines at higher concentrations, consistent with distinct mechanisms of binding underlying these differential effects. At low concentrations of CD532 and short time points, however, the loss of MYCN was apparent, whereas the levels of Aurora A protein were unaffected. These observations are consistent with the degradation of MYCN resulting from CD532 binding rather than from loss of Aurora A protein.
Histone H3 is a known substrate for both Aurora A and Aurora B. Accordingly, the dual inhibition of Aurora A and Aurora B with VX-680 abrogates the phosphorylation of histone H3 at S10. In contrast, MLN8237 caused an initial increase in S10 phosphorylation at lower concentrations, followed by a sharp drop at higher concentrations (Figures 1D; Figures S1E and S1F) . This increase in phosphorylation of histone H3 in response to MLN8237 has been described previously and results from Aurora A inhibition with feedback increase in Aurora B activity (Gö rgü n et al., 2010; Wen et al., 2012) . CD532 behaves similarly to MLN8237 with regard to histone H3 phosphorylation, consistent with an Aurora-A-selective effect.
We determined the cellular half maximal effective concentration (EC 50 ) at 72 hr against two different MYCN-amplified neuroblastoma cell lines, SK-N-BE(2) and Kelly, as 223.2 and 146.7 nM, respectively, for CD532 and as 40.89 and 33.92 nM, 
Cancer Cell
Drugging MYCN through Aurora A Inhibition respectively, for MLN8237 ( Figures 1E and 1F) . These values are directly proportionate to the cell-free IC 50 for Aurora A inhibition by CD532 (45 nM) and MLN8237 (4 nM) by $10 fold. In addition, the IC 50 of CD532 for on-target MYCN knockdown in SK-N-BE(2) cells ($250 nM; Figure 1D ) is consistent with the cellular EC 50 (223.2 nM; Figure 1E ). Notably the maximal cytotoxicity (E max ) for each compound is proportionate to the degree of MYCN knockdown rather than the degree of Aurora A inhibition in MYCN-amplified neuroblastoma lines. These data argue for an Aurora-A-dependent effect on the inhibition of cell growth and a MYCN-dependent effect on the loss of viability.
Degradation of MYCN Requires Phosphorylation and Proteasomal Degradation of MYCN
Upon the loss of the Aurora A scaffolding function by small interfering RNA (siRNA) knockdown, MYCN is degraded through canonical ubiquitination and proteasomal degradation (Otto et al., 2009) . As such, we would expect the rapid degradation of MYCN protein to occur within hours of dissociation of the MYCN-Aurora-A complex. We observed a clear and timedependent loss of MYCN protein at time points as short as 4 hr of treatment with CD532. In contrast, treatment with MLN8237, although resulting in a similarly rapid decrease in the MYCN level, causes a decrease that is more modest and that does not change over time (Figure 2A ). Treatment of MYCN-amplified IMR32 cells with increasing concentrations of CD532 in the presence of the proteasome inhibitor MG-132 shows that MG-132 protects the MYCN from degradation but has no effect on the inhibition of H3 phosphorylation ( Figure 2B ). MYCN is sequentially phosphorylated at S62 and T58 before it is ubiquitinated and targeted for degradation. However, when bound in a complex with Aurora A, ubiquitinated MYCN is protected from degradation (Gustafson and Weiss, 2010; Otto et al., 2009) . To test whether the activity of CD532 is dependent on these phospho-residues, we treated SHEP MYCN-nonamplified neuroblastoma cells engineered to express either wild-type MYCN (MYCN WT ) or a nonphosphorylatable mutant of MYCN (MYCN T58A/S62A ) with CD532. CD532 dose-dependently decreased the wildtype MYCN protein but was less effective in degrading MYCN T58A/S62A , suggesting that CD532 potentiates the loss of MYCN through the canonical phosphorylation and ubiquitination pathway. Notably, even high concentrations of VX-680, which stabilizes Aurora A in the active conformation (Zhao et al., 2008) , had little effect on MYCN protein levels in this system ( Figure 2C ).
CD532 Stabilizes a DFG-in, Inactive Conformation of Aurora A CD532 consists of an aminopyrazole-pyrimidine ATP-mimetic backbone, similar to VX-680, but includes a 3-trifluoromethylbiphenyl urea as its conformation-disrupting pharmacophore ( Figure 3A ). To determine how CD532 binding affects the conformation of Aurora A, we determined the crystal structure of the catalytic domain of Aurora A (residues 123-390) both alone (apo) and bound to CD532, to resolutions of 3.14 and 1.85 Å , respectively ( Figure 3B and Table S1 ). Although the B factor of the relatively disordered activation loop in both structures is high, the tracing of the polypeptide backbone was unambiguous. The electron density for CD532 within the active site was well defined ( Figure 3C ).
The ATP-binding hinge region of the Aurora A active site makes polar contacts with the aminopyrazole portion of CD532, consistent with our choice of ATP-mimetic scaffold. See also Movie S1 and Table S1.
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Drugging MYCN through Aurora A Inhibition The catalytic D274 achieves polar contacts with the urea moiety of CD532 to stabilize the biphenyl urea in its orientation toward the N-terminal b1 and b2 strands forming part of the ATP binding pocket (Figures 3C and 3D) . The polar contacts between the urea moiety and CD532 allow for an $7 Å displacement of the b1 and b2 strands in the N-terminal domain via steric clash with the trifluoromethylphenyl moiety of CD532 ( Figure 3E ). These b1 and b2 strands form part of a b sheet that is the core of the relatively rigid N-terminal domain. Thus displacement of these strands by CD532 disrupts the conformation of Aurora A (apo), rotating and shifting the N-terminal domain by 6.2 Å relative to the C-terminal domain ( Figure 3F ; Movie S1).
The highly conserved HRD kinase regulatory sequence is located at the lip of the active site. Coordination between this HRD arginine and a phospho-threonine in the activation loop (R255 and T288, respectively, in the case of Aurora A) orients the HRD catalytic aspartic acid to be primed for catalysis. Using this mechanism, the catalytic activity of HRD-containing kinases can be regulated through the phosphorylation of their activation loop. In the presence of CD532, R255 and T288 are displaced by a considerable distance ( Figure 3G ). In fact, CD532-bound Aurora sequesters R255 in a manner that displaces the catalytic HRD aspartic acid from its catalytically A C B D functional orientation, disengaging HRD regulation and stabilizing the kinase in a catalytically inactive conformation. Indeed, the displaced a-C helix and R255 together trap the most N-terminal portion of the activation loop in a network of hydrogen bonds ( Figure 3G ). This interaction positions the activation-loop backbone in a manner that stabilizes the entire activation loop in its inactive orientation, flipped 180 relative to its active state (Figure 3H) . Thus, CD532 stabilizes Aurora A in a distinct conformation, associated with a 6.2 Å shift in the position of the N-terminal domain relative to the C-terminal domain, a disengaged state of the regulatory HRD motif, and a 180 flip in the activation loop.
Degradation of MYCN Requires Conformation-Specific
Inhibition of Aurora A Although both VX-680 and CD532 bind to the ATP-binding hinge of Aurora A in an identical manner through their aminopyrazolepyrimidine core, each contains distinct chemical components that produce highly divergent effects on MYCN in cells ( Figures  3A and 4A ). Our crystallographic data suggest that several chemical moieties of CD532 were critical for its ability to destabilize MYCN. As expected, altering the urea moiety of CD532 decreased the biochemical potency against Aurora A as well as the efficacy against MYCN in neuroblastoma cell lines (Figure 4B) . Our structural data also show that the 6 position of the pyrimidine backbone is oriented toward the solvent and the addition of a methyl group to this position (CD15) maintained both cell-free potency and efficacy against MYCN ( Figure 4B ; Figure S2 ). These data are consistent with the degradation of MYCN occurring as a consequence of the on-target Aurora A kinase conformation-disrupting activity of CD532.
The cyclopentyl moiety of CD532 packs neatly into a hydrophobic pocket made by V147, L194, and the leucine gatekeeper (L210) ( Figure 4C ). Thus, our crystallographic data suggest that
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Drugging MYCN through Aurora A Inhibition an additional methylene and the adoption of the resulting sixmembered ring into a chair conformation would preclude binding to Aurora A without abrogating binding to other kinases with a less bulky gatekeeper. Indeed, compounds CD22 and CD24 lost both potency against Aurora A and efficacy against MYCN ( Figure 4D ; Figure S2 ).
The sterically bulky trifluoromethyl interacts with and displaces the b1 and b2 strands, which stabilizes a global conformational change in Aurora A that is unable to protect MYCN from degradation ( Figure 3E ). We hypothesized that the replacement of this group with a hydrogen would decrease the magnitude of the N-terminal displacement of Aurora A without altering the binding affinity. Indeed, CD25 retained potency against Aurora A activity, demonstrated both biochemically and by the loss of histone H3 phosphorylation, but was less effective than CD532 in driving MYCN loss, suggesting that the magnitude of the N-terminal shift of Aurora A contributes to MYCN destabilization ( Figure 4D ).
CD532 Blocks S-Phase Entry
Both Aurora A and MYCN are critical to different phases of the cell cycle, and the functional consequences of Aurora A kinase A B C D Figure 5 . CD532 Inhibits Aurora A Kinase Activity and Downregulates MYCN SK-N-BE(2) cells were treated for 6 hr with the indicated compounds at 1 mM, and EdU was added 1 hr prior to harvesting to measure the cell cycle using EdU incorporation and propidium iodide (PI) staining (A), using p-H3 (B), using pan-Aurora (A, B, and C isoforms) phosphorylation (C), and using MYCN protein (D) with flow cytometry. See also Figure S3 .
inhibition and MYCN loss are distinct. The inhibition of Aurora A blocks mitosis, causing a G2/M arrest (Manfredi et al., 2011) . In contrast, MYC family proteins drive synthesis-phase (S-phase) entry. The knockdown of MYCN protein blocks entry into the S phase, causing a subsequent G0/G1 arrest (Gogolin et al., 2013) . To compare the functional differences between conventional Aurora A kinase inhibition (MLN8237 or VX-680) and conformation-disrupting Aurora A kinase inhibition, we treated MYCN-amplified neuroblastoma cells and measured cell cycle using flow cytometry. As expected, treatment with MLN8237 or VX-680 resulted in G2/M arrest ( Figure 5A Figure 5C ), and the loss of MYCN protein ( Figure 5D ). Aurora kinase inhibitors all caused the loss of p-pan-Aurora, detectable in a small fraction of cells using flow cytometry ( Figure 5D ). All Aurora kinase inhibitors caused the loss of p-pan-Aurora, but only CD532 also caused a loss of S phase and MYCN ( Figure 5 ).
CD532 Is a MYC-Directed Therapy CD532 has the dual effect of blocking Aurora A kinase activity and driving the degradation of MYCN. To further characterize the effects of CD532 on the cell cycle, we compared it to the bromodomain inhibitor JQ1, which has been shown to block the transcriptional activity of MYCN and the transcription of MYCN itself in neuroblastoma (Puissant et al., 2013) . The treatment of MYCN-amplified neuroblastoma cells with JQ1 for 24 hr resulted in the downregulation of MYCN, blockade of S-phase entry, and accumulation of cells in G0/G1 ( Figures 6A; Figures S4A and  S4B ). The treatment with CD532 for 4 hr resulted in a rapid and potent loss of S phase (consistent with the rapid and potent loss of MYCN protein) and accumulation in both G0/G1 and G2, consistent with a mixed Aurora A and MYCN effect. Treatment with MLN8237 for 4 hr resulted in a modest downregulation of
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Drugging MYCN through Aurora A Inhibition MYCN and accumulation of cells in the G2 and M phase, which has been described previously (Manfredi et al., 2011) . When combining treatments with JQ1 for 24 hr and MLN8237 for 4 hr, an additive loss of S phase and accumulation in G2/M were observed, similar to CD532.
That the cell-cycle and viability activity of CD532, but not MLN8237, is related to the degradation of MYCN suggests that the expression of MYCN might confer sensitivity to CD532. We herefore determined the cellular EC 50 for these compounds against both GFP-and MYCN-transduced SH-EP neuroblastoma cells, which express little to no MYCN. The transduction of MYCN conferred sensitivity to CD532 but not to MLN8237 ( Figure 6B ). In addition, CD532-driven loss of S phase in these cells could be rescued by the stabilizing MYCN T58A/S26A mutant ( Figures S4C and S4D) . These data suggest that the efficacy of CD532 is due primarily to the loss of MYCN, whereas that of MLN8237 is due primarily to the inhibition of Aurora A.
To determine whether MYCN might serve as a biomarker of sensitivity to CD532, we screened a panel of 169 distinct tumor-derived and genetically characterized cell lines, including 93 lines for which the information on the MYCN copy number was available and 87 lines for which the mRNA expression data were available (Garnett et al., 2012) . CD532 showed activity in most cell lines, with the EC 50 in the nanomolar range, consistent with our results in neuroblastoma (Table S2) See also Figure S4 and Table S2. CD532 correlated with the expression of MYCN/MYC mRNA in neuroblastoma cells ( Figure S4E ). MYCN-amplified cell lines were significantly more susceptible to CD532 than were nonamplified lines (p = 0.0010). In validation of this analysis, MYCN amplified lines were significantly more susceptible to JQ1 than were nonamplified lines (p = 0.0069), whereas MYCN amplified and nonamplified lines showed similar sensitivities to VX-680 (p = 0.618; Figures S4F-S4H ). Gene-setenrichment analysis revealed that susceptibility to CD532 correlated with a MYC signature, i.e., lowest EC 50 in cells with the highest expression of MYC targets and highest EC 50 in cells with the downregulated MYC targets ( Figure 6C ). These data support a broad potential for CD inhibitors of Aurora A against tumors in addition to neuroblastoma and suggest a role for Aurora A CD inhibitors in both MYC-and MYCN-driven diseases.
CD532 Reduces MYCN and Is Effective In Vivo
Although CD532 is a compound in development and not yet optimized for in vivo pharmacokinetics, its efficacy in cell culture was substantial enough to warrant testing in vivo. Studies in mice revealed a serum half-life of $1.5 hr, providing for an area under the curve during 24 hr (AUC0-24) of 27 mM/hr when delivered at 20 mg/kg ( Figure S5A ). This is in contrast to the clinically developed MLN8237, which has an AUC0-24 of 78.4 mM/hr when delivered at the same dose (Carol et al., 2011) . Nonetheless, treatment of MYCN-amplified neuroblastoma xenografts with CD532 led to decreased levels of MYCN protein ( Figure 7A In addition to neuroblastoma, MYCN prominently drives other cancer types, including medulloblastoma (Swartling et al., 2010) . The sonic hedgehog (SHH) subtype of medulloblastoma shows a high expression of MYCN because SHH signaling promotes both the expression and posttranscriptional stabilization of MYCN (Kenney et al., 2003; Thomas et al., 2009) . In order to test activity in medulloblastoma in vivo, we treated a MYCN-expressing
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Drugging MYCN through Aurora A Inhibition SHH-subtype medulloblastoma allograft derived from Ptch +/À ; p53 À/À mice (Kim et al., 2013; Romer et al., 2004) . CD532 at 25 mg/kg twice per week substantially reduced MYCN levels, reduced tumor burden, and extended survival in these mice (Figures 7B-7D ; Figure S5C ). Notably, mice tolerated this dosing regimen without obvious short-or long-term toxicity or weight loss. Figures 1D and 2A; Figures S1E and S1F) . To test how the degree of conformational shift in Aurora A affects the binding of MYCN and Aurora A, we measured the MYCN-Aurora-A interaction in MYCN-amplified neuroblastoma cells treated with increasing concentrations of CD532 or MLN8237. CD532 inhibited histone H3 phosphorylation at concentrations 10-fold higher than MLN8237, consistent with their respective biochemical IC 50 and cellular EC 50 ( Figure 8A ). However, CD532 caused a dose-dependent and complete dissociation of the MYCN-Aurora-A complex at 2 hr, whereas MLN8237 only modestly disrupted this interaction ( Figures 8A and 8B) . This dissociation did not occur with VX-680 treatment (data not shown). The effect of CD532 on the MYCN-Aurora-A interaction was specific in that it did not affect the MYCN-MAX binding (Figures S6A and S6B) . Notably, the disruption of the MYCN-Aurora-A complex by CD532 occurred at doses comparable to those required to block p-H3, consistent with the conformation change of MYCN as a consequence of CD532 binding. This is in contrast with MLN8237, which showed only partial disruption of the complex upon maximal Aurora A inhibition ( Figure 8A ). Thus MLN8237, a more potent Aurora A binder, only modestly decreased the interaction of Aurora A with MYCN. By comparison, CD532 binds Aurora A with lower affinity but has a dramatic effect on Aurora A binding to MYCN ( Figure 8B) .
Disruption of the MYCN-Aurora-A Complex
As intended through the use of the diaminopyrimidine scaffold for screening, CD532 binds to Aurora A at the hinge region via a pyrazole moiety in a manner similar to VX-680 ( Figure 8C ) yet interacts with other parts of the Aurora A binding pocket to confer distinct biological effects (loss of MYCN, decreased viability, and loss of S phase), biophysical effects (shift in tertiary structure), and biochemical effects (disruption of the MYCN-Aurora-A complex). The data in Figure 8D demonstrate that VX-680, MLN8237, and CD532 show increasing activity in driving the destabilization of MYCN protein in MYCN-amplified cell lines. Comparing the published structures of Aurora A bound to VX-680 and to MLN8054 with our structure of Aurora A bound to CD532 demonstrates a progressive disruption of the conformation of Aurora A ( Figure 8E ). Thus, the ability of VX-680, MLN8237, and CD532 to progressively displace the a-C helix in Aurora (a structural measure that tracks directly with MYCN proteolysis) illustrates how a starting scaffold can be modified to effect divergent biochemical and biological activities.
DISCUSSION
Earlier studies of Aurora kinases clarified a central role for Aurora A in mitosis and transformation. Inhibitors of Aurora A have therefore been developed as therapeutics and are currently being tested across a range of cancers. Aurora A shares significant structural and sequence similarity with Aurora B, although these proteins have distinct mitotic functions and distinct subcellular localizations. These differences in both function and localization are attributed in part to the association of each kinase with a unique group of cofactor proteins (reviewed in Carmena et al., 2009 ).
Here we describe a class of compounds that were initially designed to bind Aurora A in a type II fashion, defined by the DFG-out orientation of D274, as a strategy for disrupting the conformation of this kinase. Thus, it was surprising to observe 
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Drugging MYCN through Aurora A Inhibition that CD532 binds Aurora A as DFG-in yet still induces a conformational disruption not achieved by nonselective tool inhibitors that induce a DFG-out conformation in Aurora A in vitro (Martin et al., 2012) . Comparing CD532-bound Aurora A to the apo structure shows the activation loop in the inactive orientation, accompanied by a shift in the entire N-terminal domain. Although the activation-loop flip is consistent with an inactive conformation of Aurora A, the urea moiety of CD532 locks the DFG motif in the active DFG-in orientation. This concurrence of features from otherwise distinct states of the kinase is achieved through a steric clash of the trifluoromethylphenyl moiety of CD532 with Aurora's N-terminal b1 and b2 strands, displacing the N-terminal lobe of Aurora A and allowing a unique network of hydrogen bonds to stabilize the activation loop in an inactive orientation. Our structural data also suggest a mechanism through which an inhibitor can stabilize the inactive conformation of a kinase. Previously described inhibitors that stabilize kinases in their inactive conformation displaced the aspartic acid of the catalytic DFG motif, with a concomitant crankshaft-like 180 rotation of the DFG backbone. In contrast, CD532 induces this inactive conformation through interaction with the b1 and b2 strands of the N-terminal domain, without reorienting the DFG motif. Our structure thus reveals an uncoupling of the DFG flip from the inactive state of a kinase. Whether such uncoupling plays a role in the physiological state of the kinase, perhaps as part of its regulation, or occurs only in the presence of specific pharmacological entities remains to be determined.
Can these specific associations be exploited to identify inhibitors of Aurora kinases that also disrupt interactions with cofactor proteins? The resulting conformation of CD532-bound Aurora A blocks both kinase-dependent and kinase-independent functions of Aurora A. CD532 inhibits Aurora A at low nanomolar concentrations and, in parallel, effects the proteolytic degradation of MYCN. Importantly, we were unable to uncouple kinase inhibition and MYCN proteolysis through the structural modification of CD532, consistent with the disruption of Aurora A's scaffold as a result of bulky pharmacophores that extend from an ATPcompetitive core.
The difference in the kinetics of complex dissociation between CD532 and MLN8237, coupled with their respective IC 50 and crystallographic information, provides insight into the biophysical basis for the disruption of the MYCN-Aurora-A interaction. Although MLN8237 is a potent inhibitor of Aurora A, it only modestly disrupts the conformation of Aurora A. In contrast, CD532 is a weaker inhibitor of Aurora A, but saturating doses lead to the complete dissociation of the complex. Taken together with the structural data, these observations suggest that the equilibrium of dissociation of the MYCN-Aurora-A complex is dependent on the degree of conformational disruption of Aurora A.
Several other inhibitors of Aurora kinase are in clinical development, all of which act as mitotic poisons much like current cytotoxic chemotherapy agents. Our functional data show that CD532 acts more as a potent MYCN inhibitor than as a conventional Aurora A inhibitor in neuroblastoma and has the potential to act as a MYC inhibitor in other cell types. Although the pharmacokinetic properties of CD532 have not been optimized, CD532 could effect the loss of MYCN protein in neuroblastoma xenografts as well as reduce tumor burden and improve survival in a mouse model of medulloblastoma, providing motivation for additional medicinal chemistry and optimization of this family of compounds for clinical use.
Neuroblastoma is the most common extracranial solid tumor of childhood, and MYCN amplification is the best-described genetic lesion marking high-risk chemotherapy-resistant disease. The targeted expression of MYCN drives neuroblastoma in mice and zebrafish (Weiss et al., 1997; Zhu et al., 2012) . We have previously finessed the destabilization of MYCN through blockade of PI3K/mTOR (Chanthery et al., 2012; Chesler et al., 2006) and have shown in vivo efficacy through an alternative approach to blocking MYCN and its transcriptional targets using BRD4-based bromodomain inhibitors (Puissant et al., 2013) . Here we propose a third strategy to block MYCN in cancer. These three interventions, at distinct nodes in the same oncogenic pathway, present a unique opportunity for combinatorial, targeted therapeutics to block emergent resistance while maximizing the blockade of MYCN in neuroblastoma and potentially in other MYCN-and MYC-driven cancers.
Allostery is most generally defined as a phenomenon whereby a perturbation by an effector at one site of the molecule leads to a functional change at another through the alteration of the shape and/or dynamics (Nussinov and Tsai, 2013) . There are several recent examples of allosteric inhibitors for the treatment of cancer, including arsenic trioxide, an antileukemic, that binds to zinc fingers within the PML-RARAa fusion protein of acute promyelocytic leukemia to induce a conformational change favoring oligomerization and eventual degradation (Zhang et al., 2010) , and biculutamide, which binds to the androgen receptor to block androgen-receptor-mediated transcription in prostate cancer (Osguthorpe and Hagler, 2011) . Enzymes, including but not exclusive to kinases such as Aurora A, may have important nonenzymatic activities, including scaffolding, regulation, and localization of other proteins. As such, many molecular interactions necessary for cellular function and carcinogenesis are not targetable directly with small molecules either because they have no amenable binding pocket (as with MYC proteins) or because their affinity for natural substrate is too high (as with many guanosine triphosphatases [GTPases] such as RAS). By contrast, orthosteric targeting of small molecules to enzymes such as kinases has become relatively trivial. Here we refer to an ATP-mimetic ligand that binds the active site of Aurora A to alter its kinase-independent stabilization of MYCN but also, obligately, its kinase activity. We propose that such an inhibitor be referred to as ''amphosteric,'' denoting an inhibitor that is simultaneously both orthosteric (inhibiting kinase activity) and allosteric (disrupting protein-protein interactions). Thus, CD532 represents the prototype of a class of amphosteric inhibitors that induce an allosteric change to disrupt the nonenzymatic functions of enzymes. Because these amphosteric effects are neglected in most current inhibitor screening, the development of small-molecule screens for other amphosteric inhibitors has the potential to target other undruggable oncoprotein targets.
EXPERIMENTAL PROCEDURES
Cell Culture, Inhibitors, and Western Blotting Neuroblastoma tumor cell lines were obtained from the University of California San Francisco Cell Culture Facility (Kelly, SK-N-BE2, and SH-EP). SMS-KCN,
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Drugging MYCN through Aurora A Inhibition SHEP MYCN wt and MYCN T58A/S62A cells were obtained from Martin Eilers lab. All cells were grown in RPMI with 10% fetal bovine serum (FBS). Neuroblastoma cells were harvested and lysed with cell signaling lysis buffer + 1% SDS, sonicated and supernatants boiled in lithium dodecyl sulfate (LDS) sample buffer (Invitrogen). Western blots were performed as described previously (Chanthery et al., 2012) , with primary antibodies to MYCN (ab24193, Abcam) , histone H3, p-histone H3 (S10), Aurora A (Cell signaling), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Millipore). Western blot quantitation was performed using ImageJ software. VX-680 (S1048) and MLN8237 (S1133) were obtained from Selleck chemicals.
Flow Cytometry and Viability
Neuroblastoma cells were treated for the indicated time, trypsinized, washed, stained with Dylight 800 at 0.3 mg/ml (Pierce, 46421), fixed with 1.5% paraformaldehyde (PFA), and permeabilized with 100% methanol. Cells were then stained with antibodies against p-MPM2 (Millipore, 16-155), p-pan-Aurora (Cell Signaling, 2914), MYCN (Thermo, PA5-17403), rabbit immunoglobin G (IgG; Invitrogen, A10542), or mouse IgG (BioLegend, 405307) . Cells were stained with DAPI at 0.3 mg/ml (Invitrogen, D21490) and analyzed on the BD LSR II flow cytometer. For cell-cycle analysis, cells were stimulated with EdU for 2 hr prior to harvest and then probed using the Click-iT EdU Flow Cytometry Assay Kit (Invitrogen, C10424). Cells were stained with propidium iodide (BD, 556547) and analyzed on the BD FACSCalibur flow cytometer. The data were gated using Cytobank. For viability studies, neuroblastoma cells were plated in 96-well plates at a density of 1,000 cells/well for SHEP or 4,000 cells/well for Kelly or SK-N-BE2 cells, and then incubated with the indicated concentrations of drug for 72 hr at 37 C. The plates were frozen at À80 C to induce cell lysis. CyQUANT reagent mixture (Invitrogen, C7026) was added to the thawed plates; then the fluorescence was measured. Alternatively, resazurin (Sigma-Aldrich, R7017) was added directly to the wells following the drug treatment; the cells were then incubated for 4 hr at 37 C prior to measuring the fluorescence. The data were analyzed using GraphPad Prism software.
Pulldowns
The cells were pretreated with MG-132 (Calbiochem, 474790) at 5 mg/ml for 4 hr and with a drug (CD532, MLN8237, or VX-680) for 2 hr before lysis with TNN lysis buffer in the presence of a protease inhibitor (Sigma-Aldrich, P8849). Pulldowns were performed with anti-MYCN antibody (Santa Cruz, SC-53993) and Protein G sepharose beads (Sigma-Aldrich, P3296). Immunoblots were performed as previously described.
Chemical Synthesis
Starting materials were purchased from Sigma-Aldrich or Alfa Aesar. Unless otherwise noted, reactions were performed in dry, argon-charged, glass round-bottom flasks and monitored using thin-layer chromatography (TLC) or liquid-chromatography-mass-spectrometry (LC-MS). Compounds were characterized using LC-MS and nuclear magnetic resonance (NMR) spectroscopy. LC-MS retention times (RTs) are reported in minutes based on a gradient of 5%-95% acetonitrile (ACN)/H 2 O from t = 0.1 min to t = 1.9 min. NMR shifts (d) are reported in parts per million as singlets (s), doublets (d), quartets (q), quintets (quin), or multiplets (m). High-performance liquid chromatography (HPLC) was conducted using a Waters 2545 binary-gradient module, Waters 2767 sample manager, and Waters 2998 photodiode array detector running MassLynx v4.1. Flash/silica gel chromatography was performed on an Ana-Logix Intelliflash using SuperFlash Si50 columns (Agilent). Synthetic procedures can be found in the Supplemental Information.
Expression and Purification of Aurora A Kinase
Purification and expression of Aurora A were performed as described previously (Martin et al., 2012) , with the following modifications. Aurora A (residues 123-390, T287D) was cloned into a pET28a plasmid providing fusion with a PreScission-Protease-cleavable hexahistidine tag. The protein was overexpressed in BL-21(DE3) cells at 18 C. Digestion with PreScission Protease was performed overnight at 4 C in a 10 kDa molecular-weight-cut-off (MWCO) dialysis cartridge (Thermo Scientific) with a dialysis buffer containing 50 mM 2-(N-morpholino)ethanesulfonic acid (MES; pH 6.5), 300 mM NaCl, and 1 mM dithiothreitol (DTT), followed by 4 hr of dialysis with a buffer containing 50 mM MES (pH 6.5) and 1 mM DTT before being loaded onto an ion-exchange column. Pooled fractions were concentrated to 5 mg/ml (Amicon Ultra, 10 kDa MWCO, Millipore) and loaded onto a HiLoad Prep Grade Superdex 200 column (GE Healthcare) equilibrated with 50 mM HEPES (pH 7.4) and 1 mM DTT to yield monomeric enzyme for use in both the kinase assays and crystallization.
In Vivo Studies
For the pharmacokinetic studies, CD532 was formulated at 20 mg/ml in 7.5% DMSO and 92.5% polyethylene glycol 300 (PEG 300). LC-MS/MS detection of CD532 was performed using a Waters 2545 binary-gradient module, Waters 2767 sample manager, and Waters 2998 photodiode array detector running MassLynx v4.1. For the neuroblastoma studies, NOD scid gamma mice (Jackson Laboratory) were implanted with 10 6 SMS-KCN cells in growth media with 50% Geltrex (Invitrogen) into renal capsule. At 21 days post implantation, tumors were palpable and treated for 2 days with 60 mg/kg CD532 before harvesting and flash freezing for analysis. For the medulloblastoma studies, homozygous nu/nu mice (Simonsen) with flank subcutaneous allografts (10 6 cells implanted per mouse) of SHH-subtype MYCN-expressing medulloblastoma were started on treatment once the tumors reached 25 mm 3 in volume ($14 days). Mice were treated with the vehicle (5% DMSO in PEG 300) or CD532 (25 mg/kg, formulated at 7.5 mg/ml) twice per week, delivered by intraperitoneal injection. Mice were euthanized once the maximum tumor length reached 2.0 cm. Difference in tumor burden was evaluated using a two-tailed student's t test, and the difference in survival was evaluated using a log-rank test. All experiments on live vertebrates or higher invertebrates were performed in accordance with relevant institutional and national guidelines and approved by the UCSF Animal Care and Use Committee (IACUC).
Crystallization and Data Collection
After gel separation, the purified fractions of Aurora A were pooled and concentrated in the presence of the drug to a final concentration of 20 mg/ ml Aurora A and 1 mM drug. All crystallization reagents were obtained from Hampton Research (Aliso Viejo). Crystals were generated using hangingdrop vapor diffusion at room temperature using a 1:1 mixture of protein solution and well solution. For Aurora A Apo, the well solution consisted of 10% Tacsimate (pH 7.0) and 20% PEG 3,350. For Aurora A with CD532, the well solution consisted of 0.2 M magnesium acetate tetrahydrate, 0.1 M sodium cacodylate trihydrate, and 20% w/v PEG 8,000 (pH 6.0). Crystals did not grow in the apo conditions in the presence of drug or in the drug conditions in the absence of compound. CD532-bound and apo crystals were cryoprotected with well solution supplemented with 10% and 25% ethylene glycol, respectively, and stored in liquid nitrogen. The diffraction data were recorded on Beamline 8.2.2 at the Lawrence-Berkeley Advanced Light Source at a temperature of 100 K and wavelength of 1.0088 nm. The data were indexed using HKL2000 (HKL Research). The drug-bound crystals belong to the C2221 space group with one monomer in the asymmetric unit, and Apo crystals belong to the P31 space group with four monomers in the asymmetric unit. Molecular replacement and refinement were performed using Phaser-MR and phenix.refine in PHENIX (Adams et al., 2010) , model building was performed using Coot (Emsley et al., 2010) , and figures were drawn using MacPYMOL 1.5.0 (Schrodinger). RCSB validation reports are shown in the Supplemental Information. Procedures for chemical synthesis, gene-setenrichment analysis, and in vitro kinase assays are described in the Supplemental Information.
ACCESSION NUMBER
Atomic coordinates and structure factors for CD532-bound and apo Aurora A have been deposited in the Protein Data Bank as 4J8M and 4J8N, respectively. 
SUPPLEMENTAL INFORMATION
Cancer Cell
Drugging MYCN through Aurora A Inhibition Movie S1, related to Figure 3 . Provided as an MPEG file. CD532 stabilizes an inactive conformation of Aurora A. Morph of apo structure of CD532 (4J8N) to CD532-bound structure (4J8M). GSEA software (Subramanian et al., 2005) was used to identify groups of functionally related genes correlated with sensitivity to CD-532. GSEA was run on these 87 cell lines using the collections of 4,722 curated gene sets (C2) and 615 transcription factor targets (C3) from MSigDB (v4.0). Using the individual EC 50 of each cell line as a continuous phenotype, genes were ranked using Pearson's correlation, and P values were calculated using 1,000 gene set permutations. Gene sets with less than 15 genes or more than 500 genes were excluded from the analysis. Gene sets with an FDR ≤ 0.05 and a nominal P ≤ 0.05 were considered significant.
Supplemental Data
Cell-line status for MYCN amplification and drug sensitivity data for VX-680 were downloaded from the Genomics of Drug Sensitivity in Cancer website. Cell-line sensitivity to JQ1 has been previously published (Puissant et al., 2013) . Amplified cells possessed MYCN copy number ≥ 8. The significance of sensitivity of CD-532 (EC 50 calculated using the four-parameter log-logistic function in R using the "drc" package), JQ1, and VX-680 in relation to MYCN amplification status was assessed using the Wilcoxon Rank Sum test in R.
In vitro kinase assays
Kinase assays for Aurora A were performed in 10 mM HEPES pH 7.5, 10 mM MgCl 2 , 0.01% Triton, 4% v/v DMSO, 5 nM kinase, and either 4 µM histone H3 or 30 µM synthetic peptide AKRRRLSSLRA (Elim Biopharmaceuticals, Inc). Drug concentration ranged from 2000-5 nM. Reactions were preincubated with inhibitor for ten minutes before initiation by addition of 100 µM nonradioactive ATP supplemented with 32 P ATP (1 mCi in 200 µL, Perkin-Elmer, 0.8 µCi per reaction). Reactions were quenched at 10 min by spotting 3 µL quantity onto P81 phosphocellulose (Whatman), which were washed 5x5' in 0.1% phophoric acid and dried. Radioactivity was measured by phophorimaging and recorded on a Typhoon fluorescence imager (Molecular Dynamics). Data were quantified using Spot (Knight et al., 2007) and fit to a sigmoidal doseresponse curve using Prism software (GraphPad Software, Inc) to obtain IC 50 values.
Synthetic Procedures
CD532, CD25:
3-cyclopentyl-3-oxopropanenitrile (JM2)
To a dried, argon-charged roundbottom flask with large stir bar was added anhydrous tetrahydrofuran (160 ml), which was then cooled to -78° C before addition of 2.5 M n-Butyllithium in hexanes (64 mL, 160 mmol). Reaction was stirred for 5 minutes before addition of anhydrous acetonitrile (8.48 mL, 160 mmol) dropwise over 5 minutes. and reaction was stirred overnight under argon gas. Crude product was purified by HPLC (10-75% ACN/H2O) and 3.6 mg of NHC53-2 (6.89 μmol, 17% yield) was recovered as a white powder. LCMS (RT=1.32): 522.2 (100%); 523.3 (30%); 524.4 (5%). NMR, 1H, DMSO (400 MHz): 9.69 (s, 1H), 9.51 (s, 1H), 9.29 (s, 1H), 8.94 (s, 1H), 8.25 (s, 1H), 8.04 (s, 1H), 7.91 (d, 1H), 7.65-7.51 (m, 3H), 7.45 (quin, 1H), 7.40-7.32 (m, 2H), 7.23 (d, 1H), 6.32 (s, 1H), 6.19 (s, 1H), 2.93 (quin, 1H), 2.06-1.39 (m, 8H). 3-[4-({4-[(5-cyclopentyl-1H-pyrazol-3-yl) amino]pyrimidin-2-yl}amino)phenyl]-1phenylurea (CD25) JM8 (3.0 mg, 8.95 μmol) was dissolved in dry DMF (3 ml) in a dry, argon-charged flask, and isocyanatobenzene (1.07 μl, 9.84 μmol) was added. Reaction was stirred at ambient temperature for 1 hour under positive pressure. Solvent was evaporated under reduced pressure, and product was purified by HPLC (30-70% ACN/H2O) to recover 0.7 mg (17% yield) of a white powder. LCMS (RT=1. 5-cyclopentyl-1H-pyrazol-3-amine (1.51 g, 10 mmol) and 2,4-dichloro-6methylpyrimidine (1.63 g, 10 mmol) were dissolved in a 1:1 mixture of THF:H2O (70 ml) and treated with KOAc (29.45 g, 300 mmol). Reaction was stirred vigorously at 55° C for 48 hr. Layers were separated, organic layer was evaporated under reduced pressure, and resulting solid was purified by flash chromatography (2-10% MeOH/CHCl3) to afford 1.69 g (61% yield) of a white powder. LCMS (RT=1.26): 277.2 (100%); 279.2 (60%); 278.3 (25%); 280.2 (8%). NMR, 1H, DMSO (400 MHz): 8.28 (s, 1H), 7.35 (s, 1H), 6.64 (s, 1H), 5.25 (s, 1H), 2.05 (s, 3H), 1.72-1.51 (m, 8H).
N2-(4-aminophenyl)-N4-(5-cyclopentyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine (JM14) 2-chloro-N-(5-cyclopentyl-1H-pyrazol-3-yl)-6-methylpyrimidin-4-amine (73 mg, 0.26 mmol) and p-phenylenediamine (56.2 mg, 0.52 mmol) were dissolved in n-BuOH (3 mL) and stirred at 90° C for 5 hours. Reaction was allowed to cool to ambient temperature, solvent was evaporated under reduced pressure, and product was purified by HPLC (10-75% ACN/H2O) to afford 33 mg (36% yield) of JM14. LCMS (RT=0.84): 349.3 (100%); 350.3 (22%); 351.3 (4%). NMR, 1H, CDCl3: 8.54 (s, 1H), 7.20 (d, 2H), 6.62 (d, 2H), 2.90 (quin, 1H), 2.22 (s, 3H), 1.98-1.93 (m, 2H), 1.75-1.43 (m, 6H).
1-(4-((4-((5-cyclopentyl-1H-pyrazol-3-yl)amino)-6-methylpyrimidin-2-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea (CD15)
To a dry, argon-charged roundbottom flask with stir bar was added JM14 (17 mg, 0.049 mmol) and dry DMF. 3-(trifluoromethyl)phenyl isocyanate (13.3 μL, 1.1 eq) was added by syringe and reaction was stirred under argon until depletion of JM14 by LCMS (2 hours). Solvent was evaporated under reduced pressure and solid was
